Vitrolife AB (VITR) - Total Assets
Based on the latest financial reports, Vitrolife AB (VITR) holds total assets worth Skr11.30 Billion SEK (≈ $1.22 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vitrolife AB - Total Assets Trend (2000–2025)
This chart illustrates how Vitrolife AB's total assets have evolved over time, based on quarterly financial data. Also see how much is Vitrolife AB worth for the company's overall valuation and market capitalisation.
Vitrolife AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Vitrolife AB's total assets of Skr11.30 Billion consist of 18.8% current assets and 81.2% non-current assets. Review VITR total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr809.00 Million | 7.3% |
| Accounts Receivable | Skr749.00 Million | 6.7% |
| Inventory | Skr413.00 Million | 3.7% |
| Property, Plant & Equipment | Skr515.00 Million | 4.6% |
| Intangible Assets | Skr3.83 Billion | 34.5% |
| Goodwill | Skr4.44 Billion | 39.9% |
Asset Composition Trend (2000–2025)
This chart illustrates how Vitrolife AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Vitrolife AB for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vitrolife AB's current assets represent 18.8% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, up from 6.7% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 73.0% of total assets, an increase from 27.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 39.9% of total assets.
Vitrolife AB Competitors by Total Assets
Key competitors of Vitrolife AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Stratec SE
XETRA:SBS
|
Germany | €408.98 Million |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
DRTECH Corporation
KQ:214680
|
Korea | ₩235.84 Billion |
|
Novacyt
PA:ALNOV
|
France | €40.28 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
Vitrolife AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.64 | 3.41 | 21.40 |
| Quick Ratio | 2.91 | 2.73 | 20.44 |
| Cash Ratio | 0.00 | 1.44 | 19.40 |
| Working Capital | Skr1.59 Billion | Skr1.54 Billion | Skr5.01 Billion |
Vitrolife AB - Advanced Valuation Insights
This section examines the relationship between Vitrolife AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.50 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -36.2% |
| Total Assets | Skr11.12 Billion |
| Market Capitalization | $1.33 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Vitrolife AB's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vitrolife AB's assets decreased by 36.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vitrolife AB (2000–2025)
The table below shows the annual total assets of Vitrolife AB from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr11.12 Billion ≈ $1.20 Billion |
-36.24% |
| 2024-12-31 | Skr17.45 Billion ≈ $1.88 Billion |
+6.84% |
| 2023-12-31 | Skr16.33 Billion ≈ $1.76 Billion |
-20.54% |
| 2022-12-31 | Skr20.55 Billion ≈ $2.21 Billion |
+5.78% |
| 2021-12-31 | Skr19.43 Billion ≈ $2.09 Billion |
+742.87% |
| 2020-12-31 | Skr2.31 Billion ≈ $248.06 Million |
+7.78% |
| 2019-12-31 | Skr2.14 Billion ≈ $230.16 Million |
+25.99% |
| 2018-12-31 | Skr1.70 Billion ≈ $182.67 Million |
+19.34% |
| 2017-12-31 | Skr1.42 Billion ≈ $153.08 Million |
+13.75% |
| 2016-12-31 | Skr1.25 Billion ≈ $134.57 Million |
+18.06% |
| 2015-12-31 | Skr1.06 Billion ≈ $113.99 Million |
+8.92% |
| 2014-12-31 | Skr972.48 Million ≈ $104.65 Million |
+99.36% |
| 2013-12-31 | Skr487.81 Million ≈ $52.50 Million |
+5.54% |
| 2012-12-31 | Skr462.20 Million ≈ $49.74 Million |
-0.98% |
| 2011-12-31 | Skr466.78 Million ≈ $50.23 Million |
+8.71% |
| 2010-12-31 | Skr429.39 Million ≈ $46.21 Million |
+19.50% |
| 2009-12-31 | Skr359.31 Million ≈ $38.67 Million |
+4.86% |
| 2008-12-31 | Skr342.66 Million ≈ $36.88 Million |
+14.43% |
| 2007-12-31 | Skr299.46 Million ≈ $32.23 Million |
+10.49% |
| 2006-12-31 | Skr271.03 Million ≈ $29.17 Million |
+28.23% |
| 2005-12-31 | Skr211.37 Million ≈ $22.75 Million |
+13.92% |
| 2004-12-31 | Skr185.54 Million ≈ $19.97 Million |
+0.84% |
| 2003-12-31 | Skr184.00 Million ≈ $19.80 Million |
-2.40% |
| 2002-12-31 | Skr188.51 Million ≈ $20.29 Million |
-42.53% |
| 2001-12-31 | Skr328.04 Million ≈ $35.30 Million |
+89.38% |
| 2000-12-31 | Skr173.22 Million ≈ $18.64 Million |
-- |
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware … Read more